Glenmark to conduct phase III trials of nasal spray which it claims can treat COVID-19

In a major development in COVID medicine field, Glenmark Pharmaceuticals said that it will be conducting a Phase III trial on a nasal spray claiming to be effective in treatment of COVID-19. Earlier last week, company h sought emergency approval for import and marketing of nasal spray from drug regulator. pharma company has w been recommended to hold phase III trials by authorities.

Glenmark nasal spray phase III trials

Glenmark Pharmaceuticals has w joined hands with Canian company Satize, after subject expert committee (SEC) recommended company to conduct Phase III trial. As per ANI reports, company said that y will continue to evaluate in-licensing for or products along with nasal spray in pipeline.

company also shed light on positive response to its earlier introduction in COVID treatment medicine. Glenmark in a statement said, "We continue to evaluate various in-licensing opportunities across our focus segments. We have always led from front in fight against COVID-19 pandemic which is demonstrated by strong support Fabiflu has received from doctors and patients in treatment of mild to moderate Covid-19."

Speaking about its partnership with Canian pharma firm Satize and ors, Glenmark said, "We are exploring various partnerships including one with Satize which can help in protecting Indian population from SARS-COV-2 virus and reducing impact of this pandemic on our society." Satize has alrey launched its nasal spray across countries claiming that spray is effective in killing virus in largely upper airways. company also claims that nasal sprays effective in antiviral treatment of COVID-19 transmission.

Glenmark Pharmaceuticals was one of first Indian companies to come up with a COVID medicine. company in July 2020, h launched first antiviral drug 'Favipiravir', under brand name 'FabiFlu', for treatment of COVID-19 patients. Mumbai-based company h claimed that it was first oral Favipiravir-approved medication by  Drugs Controller General of India.

IM: PIXABAY/ SHUTTERSTOCK